GUEST CONTRIBUTORS

  • Implementing An End-To-End Clinical Development Process Framework
    Implementing An End-To-End Clinical Development Process Framework

    If we take for granted that there will always be new and changing processes, systems, and digital platforms and the organizational complexity within Big Pharma will not abate, how do we ensure we optimize the entire clinical trial process and make the best use of our technology and process investments?

  • Key Takeaways From FDA’s New Guidance On First-In-Human Multiple Expansion Cohort Trials
    Key Takeaways From FDA’s New Guidance On First-In-Human Multiple Expansion Cohort Trials

    The FDA published a new draft guidance on August 10, 2018 entitled, Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics. The comment period for the draft guidance closed on October 12, 2018 and approximately 20 comments were submitted to the docket. The guidance provides sponsors with recommendations for designing and conducting first-in-human (FIH) multiple expansion cohort trials within their oncology development programs.

  • Real World Evidence And The Collision Between Pharma R&D And Healthcare
    Real World Evidence And The Collision Between Pharma R&D And Healthcare

    The true effect of an intervention is often not seen until real-world usage takes place, but with such a delay between R&D and healthcare delivery, how can the industry close the gap? And what is needed to deliver more effective interventions that patients really want?

More From Guest Contributors

CLINICAL TRIAL WHITE PAPERS

More Clinical Trial White Papers

ABOUT CLINICAL LEADER

Welcome to Clinical Leader, the premier online community that helps streamline clinical research by connecting trial sponsors and cutting edge service providers. Clinical Leader is part of the Life Science Connect media group. The vision of Life Science Leader and Life Science Connect is to help facilitate connections and foster collaborations in pharmaceutical and medical device development to find ways to get more life-saving and life-improving therapies to market. Connect, Collaborate, Contribute.

Visitors are enriched with valuable information on CRO, Pre-Clinical Contract Research Organization, Bio-Analytical Contract Research Organization, Clinical Contract Research Organization, Pharmacovigilance, Clinical Data Management, Electronic Patient Reported Outcomes (ePRO), Point-of-Care Testing (POCT), Patient Recruitment, Electronic Data Capture (EDC), Clinical Trials Management Systems (CTMS) and more that can improve your business and make it more profitable.

Please take a moment to join our community and discover the benefits of your free membership.

CONNECT WITH US


@EDCLINICAL

INDUSTRY INSIGHTS

  • What Makes A Good Data Manager?
    What Makes A Good Data Manager?

    In this blog, Paul Fardy, Executive Director of Data Management at Cytel shares his thoughts on how the data manager role has evolved.

  • 10 Things We’ve Learned In 10 Years Of E-Clinical Innovation: Part 1
    10 Things We’ve Learned In 10 Years Of E-Clinical Innovation: Part 1

    Trial Interactive turns 10 this year and we could not be more proud—from an early eTMFinnovator to an end-to-end e-clinical platform, we’ve grown tremendously. Part of that growth was in realizing early that effective e-clinical innovation is powered by partnership and collaboration, which has been possible with 25+ years’ experience in the life sciences industry and 10 years of experience in e-clinical innovation.

  • In The Midst Of This: The Data Management Perspective On The Interim Analysis
    In The Midst Of This: The Data Management Perspective On The Interim Analysis

    Patti Arsenault, Cytel's Global Head of Data Management, shares her thoughts on the three core elements important for the success from the data management standpoint - effective timeline management, thoughtful database design, and a proactive approach to data cleaning.

  • Critical Operational Considerations For Interim Analyses
    Critical Operational Considerations For Interim Analyses

    Highlights from Adam Hamm, Director Biostatistics at Cytel, presentation on best practices and operational considerations for adaptive designs and interim analyses.

  • Addressing The Problem Of Feature Selection Using Genetic Algorithms
    Addressing The Problem Of Feature Selection Using Genetic Algorithms

    In the new era of big and complex data, conventional methods of solving search problems are sometimes ineffective.Genetic algorithms provide a highly effective solution to many such problems, and therefore their popularity and adoption are on the rise.

More Industry Insights

LIFE SCIENCE INDUSTRY EVENTS

Annual Cardiologists Meeting 2018 November 26 - 27, 2018
Madrid)
Blockchain Technology for the Life Sciences: A Comprehensive Primer November 27 - 27, 2018
1pm-2:30pm EST, Online Training)
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
More Industry Events

TRAINING COURSES

Blockchain Technology for the Life Sciences: A Comprehensive Primer November 27 - 27, 2018
1pm-2:30pm EST, Online Training
Adverse Event Reporting: Avoiding Common Pitfalls December 11 - 11, 2018
1pm-2:30pm EST, Online Training
More Upcoming Courses